Current Studies on Stem Cells for Osteoarthritis (2023–2025)
Kim Ki-In et al. (2023) – Phase-III-Study
In a placebo-controlled clinical study, patients treated with autologous adipose-derived stem cells showed significantly reduced pain, improved joint function, and excellent tolerability. The authors consider stem cells a promising regenerative therapy for knee osteoarthritis.
Huang Ziyu et al. (2023) – Network Meta-Analysis
The analysis of randomized studies showed that stem cell therapies can be effective regardless of the cell source. Patients with early to moderate osteoarthritis especially benefited from a significant improvement in symptoms.
Xie Ronghua et al. (2024) – Systematic Review and Meta-Analysis
The authors analyzed numerous clinical studies and concluded that mesenchymal stem cells can reduce pain, improve mobility, and may help slow the progression of osteoarthritis.
Bahram Sadeghirad et al. (2024) – Meta-Analysis of Randomized Studies
This analysis confirmed that patients with chronic osteoarthritis pain more frequently achieved clinically relevant pain relief and improved quality of life after stem cell therapy compared with control groups.
Ming Cao et al. (2025) – Meta-Analysis of Randomized Studies
The most recent meta-analysis to date shows that intra-articular mesenchymal stem cells can significantly reduce pain, improve joint function, and demonstrate a very favorable safety profile. The authors describe stem cells as a promising biological therapy for knee osteoarthritis.
Rahmadian R et al. (2025) – Dose Meta-Analysis
The study showed a moderate to large clinical benefit following stem cell injections. In particular, doses of up to 25 million cells achieved excellent results in terms of pain reduction and improved joint function.
Autism & Stem Cells – Current Studies (2022–2025)
Qu et al. (2022) – Meta-Analysis
Showed improvements in autism assessment scales and no clear increase in serious adverse effects; larger studies were recommended.
Akat & Karaöz (2023) – Systematic Review
Summarized clinical cell therapy applications in autism. Many studies reported positive trends, particularly in communication, social behavior, and daily functioning.
Saisa, Pradhani & Shen (2024) – Systematic Review and Meta-Analysis
Hematopoietic stem cells appeared relatively safe; however, the authors noted potential while emphasizing that effectiveness has not yet been clearly proven.
Wikarska et al. (2024) – Review
Presented new biological explanation models: stem cells may act through immunomodulation, neuroinflammation regulation, and pathways such as purinergic signaling.
Liu et al. (2025) – Review Article
Described stem cells as a promising approach due to their potential influence on inflammation and immune processes within the nervous system.
Nguyen et al. (2025) – Phase-II-Study
Investigated autologous bone marrow-derived cells combined with stimulation therapy. Results indicated improvements in behavior and development, with an overall favorable safety profile.
Inflammaging & Stem Cells – Studies (2020–2026)
Lee et al. (2020)
Showed that aging stem cells can contribute to inflammatory processes. The positive aspect: this is exactly where new anti-aging and regenerative strategies may have potential.
Yeo et al. (2021)
Described MSC stem cells as promising because they may regulate the immune system and positively influence age-related inflammation.
Garay (2023)
Summarized clinical studies on stem cells in aging processes. Particularly promising: positive signals regarding frailty and physical function in aging.
Lyamina et al. (2023)
Explained that MSCs may be both part of the inflammaging problem and part of the solution—depending on how young, active, and functional the cells are.
Zhu et al. (2024)
Phase I/II study: Umbilical cord MSCs were well tolerated and improved physical performance, quality of life, and inflammatory markers such as TNF-α and IL-17.
El Assaad et al. (2024)
Scoping Review: MSCs show anti-aging potential as they may positively influence chronic inflammation, cellular aging, and repair processes.
Li et al. (2023)
Large review on inflammaging: Chronic, low-grade inflammation is considered an important driver of many age-related diseases—and controlling it is viewed as a potential anti-aging strategy.
Wang et al. (2025)
Review: MSCs show potential in diseases associated with immune aging, including frailty and severe inflammatory conditions.
Han et al. (2025)
Describe MSCs as regenerative “signaling cells”: they release messenger molecules and vesicles that may reduce inflammation, promote repair, and regulate immune cells.
Ruiz et al. (2026)
Randomized Phase 2b study with Lomecel: Stem cell therapy improved physical function in older adults with frailty—a promising clinical advancement.
Current Studies on Collagen for Skin (2015–2026)
Asserin et al. (2015)
One of the first high-quality studies showed that orally consumed collagen peptides can improve skin hydration, reduce fine wrinkles, and support the skin’s collagen structure.
Choi et al. (2019) – Systematic Review
The authors evaluated numerous clinical studies and concluded that oral collagen supplements show promising effects on skin aging and wound healing.
de Miranda et al. (2021) –Meta-Analysis
The analysis of 19 randomized studies showed that hydrolyzed collagen can significantly improve skin elasticity, hydration, and the appearance of wrinkles after approximately 90 days.
Pu et al. (2023) – Meta-Analysis
Confirmed the positive effects on skin hydration, elasticity, and visible signs of skin aging. The authors consider collagen a beneficial addition to a healthy skincare routine.
Ravindran et al. (2026) – Umbrella Review (113 Randomized Studies)
The most comprehensive analysis to date concluded that collagen supplements provide clinically relevant benefits for skin, muscles, bones, and joints. The most consistent results were observed for skin elasticity, hydration, and structure.
Collagen for Joints and Osteoarthritis – Studies (2008–2026)
Clark et al. (2008) (Foundational Study, Still Frequently Cited)
Athletes with joint discomfort reported less pain and improved joint resilience after regular intake of collagen hydrolysate.
García-Coronado et al. (2019) – Meta-Analysis
Patients with osteoarthritis experienced noticeable pain reduction and improved joint function.
Ravindran et al. (2026)
The latest comprehensive analysis confirms that collagen supplementation in osteoarthritis and musculoskeletal conditions is consistently associated with improvements in pain, mobility, and function.
Inflammaging – Important Studies and Milestones (2000–2026)
Claudio Franceschi et al. (2000)
First introduced the term “inflammaging”. They described how the body increasingly shifts toward a chronic inflammatory state with age, influencing the aging process.
Claudio Franceschi & Colleagues (2014)
Showed that inflammaging is an important risk factor for many age-related diseases, including cardiovascular diseases, diabetes, osteoarthritis, Alzheimer’s disease, and frailty.
Claudio Franceschi et al. (2018)
Explained that inflammaging is driven by multiple factors—including cellular aging, metabolism, the gut microbiome, and environmental influences. The authors identified inflammation as a key driver of biological aging.
Luigi Ferrucci et al. (2018)
Showed that chronic inflammation is strongly associated with frailty, muscle weakness, and cardiovascular diseases. At the same time, they emphasized that reducing inflammation may support healthier aging.
Tamas Fulop et al. (2021)
Described inflammaging as a natural change of the immune system that can be positively influenced by lifestyle and emerging therapeutic approaches.
Kerry A. Walker et al. (2022)
Showed that chronic inflammation is closely linked to brain aging and neurodegenerative diseases. At the same time, this opens new opportunities for preventive and regenerative therapies.
Claudio Franceschi and International Expert Groups (2023–2025)
Recent reviews confirm that inflammaging is now considered one of the key hallmarks of aging. At the same time, there is growing interest in targeting this process through nutrition, exercise, microbiome therapies, senolytics, and stem cell therapies.
ODF – Important Studies and Reviews (2021–2025)
Özakar et al. (2021) – Current Overview of Oral Thin Films
The authors describe ODFs as one of the most innovative dosage forms. They highlight rapid drug release, high patient convenience, and the potential for improved bioavailability of suitable active ingredients.
Singh et al. (2022) – Comprehensive Review on Oral Dissolving Films
This review shows that ODFs can partially bypass the first-pass effect through absorption via the oral mucosa. This may increase bioavailability and enable a faster onset of action compared with conventional tablets or capsules, depending on the active ingredient.
Bahraminejad et al. (2025) – Sublingual and Buccal Delivery
The authors summarize over 75 years of research and confirm that absorption through the oral mucosa is an established strategy to deliver active ingredients faster and more efficiently into the bloodstream while partially bypassing first-pass metabolism.
Kumar et al. (2025) – Therapeutic Potential of Orally Dissolving Films
The authors describe ODFs as a modern dosage form of the future. Advantages include rapid dissolution, easy administration without water, high patient acceptance, and—for suitable substances—the possibility of improved bioavailability and faster onset of action.
Li et al. (2025) – Advances in Oral Dissolving Film Research
This review confirms that ODFs may provide advantages over traditional oral dosage forms and can be particularly suitable for older adults, children, and individuals with swallowing difficulties.
